A comprehensive view of Boehringer Ingelheim GmbH. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Boehringer Ingelheim partners with Shanghai RAAS for the development and clinical production of hemophilia drug SR604 injection; the drug has received approval for Phase I clinical trial targeting hemophilia and congenital factor VII deficiency

AAFA releases statement on asthma inhaler price caps, advocates for change in drug pricing to make medicines more affordable; group lauds Boehringer Ingelheim's US$35 per month cap on out-of-pocket costs for its COPD and asthma inhaler portfolio

Boehringer Ingelheim to cap US patients' out-of-pocket costs for inhaler products at US$35 per month, reduce certain list prices and continue significant discounts to insurers; the move follows criticisms of high inhaler costs by a US Senate committee

Boehringer Ingelheim commits €120.0M to expand its Koropi, Greece, plant to boost Jardiance production and increase capacity for certain drugs in late-stage development; the expansion is expected to add 110 new jobs

Boehringer Ingelheim and 3T Biosciences enter into US$538.5M deal to develop new cancer immunotherapies; 3T will provide patient-derived TCR data for Boehringer's TcEs, oncolytic viruses, and cancer vaccine research

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count